Active, Not Recruiting
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL
NCT04624958
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Guangdong General Hospital Guangzhou, Guangdong, China
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
- The First Affiliated Hospital of Guangdong Pharmaceutical University Guangzhou, Guangdong, China